Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06075810
Other study ID # MBQ-ABC001
Secondary ID CDMRP-BC220292
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 9, 2023
Est. completion date October 31, 2024

Study information

Verified date November 2023
Source MBQ Pharma
Contact Scott Houston
Phone (415) 404 8838
Email scott.houston@mbqpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.


Description:

The main questions this clinical trial aims to answer are: - What, if any, are the side effects of different dose levels in humans? - What is the maximum tolerated dose? - How does the human body process the drug? - Does the drug slow, stop or eliminate cancer in human participants? Participants will be asked to: - provide informed consent - be evaluated by physicians and provide laboratory specimens to determine if eligible - take MBQ-167 orally twice a day for at least 21 days - may continue dosing, if safe to do so, until not effective or other decision to stop is made - participate in multiple visits that include additional evaluations, laboratory tests and diary review until after stopping the investigational drug


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date October 31, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Key Inclusion Criteria: - The investigator will evaluate these and other criteria to determine whether a participant can be included in this study. - Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available. - Participants with known brain metastases may be eligible if specific conditions are met. - Life expectancy =6 months, in the opinion of the investigator, after starting MBQ-167. - Are able to swallow capsules twice daily. Key Exclusion Criteria: - The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study. - Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167. - Females who are pregnant or breastfeeding. - Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 30 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment. - Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 30 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment. - Active malignancies other than advanced breast cancer will be excluded from the study.

Study Design


Intervention

Drug:
MBQ-167
MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42

Locations

Country Name City State
Puerto Rico FDI Clinical Research San Juan

Sponsors (2)

Lead Sponsor Collaborator
MBQ Pharma Congressionally Directed Medical Research Programs

Country where clinical trial is conducted

Puerto Rico, 

References & Publications (6)

Borrero-Garcia LD, Del Mar Maldonado M, Medina-Velazquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 1;21(1):652. doi: 10.1186/s12885-021-08366-7. — View Citation

Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernandez-O'Farrill E, Vlaar CP, Dharmawardhane S. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer. Mol Cancer Ther. 2021 Dec;20(12):2420-2432. doi: 10.1158/1535-7163.MCT-21-0348. Epub 2021 Oct 4. — View Citation

Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Mol Cancer Ther. 2017 May;16(5):805-818. doi: 10.1158/1535-7163.MCT-16-0442. — View Citation

Maldonado MDM, Dharmawardhane S. Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res. 2018 Jun 15;78(12):3101-3111. doi: 10.1158/0008-5472.CAN-18-0619. Epub 2018 Jun 1. — View Citation

Medina JI, Cruz-Collazo A, Del Mar Maldonado M, Gascot TM, Borrero-Garcia LD, Cooke M, Kazanietz MG, O'Farril EH, Vlaar CP, Dharmawardhane S. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42. Cancer Res Commun. 2022 Dec;2(12):1711-1726. doi: 10.1158/2767-9764.crc-22-0303. Epub 2022 Dec 29. — View Citation

Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martinez-Ferrer M, Dorta-Estremera SM, Dharmawardhane S. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models. Front Oncol. 2023 Jun 16;13:1152458. doi: 10.3389/fonc.2023.1152458. eCollection 2023. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) To find the maximum tolerated dose (MTD) of MBQ-167 as a single agent administered orally, BID continuously for 21 days in participants with Advanced Breast Cancer (ABC) by evaluating for the presence or absence of dose-limiting toxicity (DLT) related to MBQ-167 administered in cohorts of participants at escalating sequential cohort dose levels. 21 days
Secondary MBQ-167 PK parameter (Cmax/min) Maximum and minimum observed plasma concentration at steady state 56 days
Secondary MBQ-167 PK parameter (tmax) Time to maximum plasma concentration 56 days
Secondary MBQ-167 PK parameter (t1/2) Terminal elimination half-life 56 days
Secondary MBQ-167 PK parameter (AUC (0-t,0-24,8)) Area under the concentration-time curve over the dosing interval time from time 0 56 days
Secondary MBQ-167 PD parameter (differential gene expression) Observed quantitative measurement of gene expression change from baseline 16 days
Secondary MBQ-167 PK/PD parameter (minimum dose for therapeutic response) Correlate differential gene expression change, objective response and PK parameter Cmax/min to identify a minimum dose for therapeutic response 56 days
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2